Stock Market Review 29AUG #shorts

Eating your greens could trump genetics in fighting fatty liver disease, new study suggests

A recent longitudinal study using data from the U.K. Biobank explores the interplay between plant-based diets and genetic predisposition in affecting the risk of non-alcoholic

September 19, 2023

Anti-VEGF for Diabetic Retinopathy and Risk for Systemic Adverse Events

A presentation during the recent American Society of Retina Specialists (ASRS) annual meeting confirmed a recent report linking anti-vascular endothelial growth factor (VEGF) drugs to

August 16, 2023

Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America

Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million. Meitheal spun out Xentria in 2020,

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.